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Genetic defects in human cells can be addressed by gene therapy in one of two ways: correction of the faulty gene (by gene targeting) or addition of a functional or therapeutic gene (gene augmentation). [1] [2] [3] Gene targeting is currently the only procedure that can produce predefined alterations in the genome of eukaryotic cells. As such, gene targeting is an attractive approach to gene therapy of genetic diseases because: (1) it can lead to the accurate correction of the defect in the target locus of interest; (2) it can correct both recessive and dominant mutations, unlike gene augmentation, which is restricted to recessive defects; (3) it is not restricted by the size of the mutated gene since only the damaged portion need be considered; gene augmentation requires delivery of the entire coding region which may be impractical for large genes; (4) actual correction of the faulty gene would permanently reverse the genetic disorder by restoring production of the normal protein product; the corrected gene would be under the control of its own regulatory sequences, thereby avoiding the potential problems of nonphysiological gene expression and long-term gene inactivation frequently associated with gene augmentation procedures; 4 and (5) it avoids the risk, associated with many gene augmentation approaches, of a harmful mutation caused by the chance integration of the therapeutic DNA at a sensitive genomic site such as an oncogene.
A potential drawback of gene correction by gene targeting is that it requires previous knowledge about the location and type of mutation to be corrected, and may
Correspondence: ACG Porter require the use of different therapeutic DNA for different patients with the same disease. Also, although it can be a high fidelity procedure, 5 mutations associated with gene targeting have been observed. 6 The main handicap, however, lies in the inefficiency of gene targeting which typically ranges from 10 −5 to 10 −7 targeted cells per transfected cell. 7 The scale of this handicap is apparent when one considers that gene augmentation involving viral vectors can result in high percentages (Ͼ10%) of cells incorporating the gene into the genome.
Two complementary strategies can be envisaged to overcome this problem: (1) improvement of gene targeting techniques, leading to higher frequencies; and (2) targeting of human somatic stem cells in culture, including their selective amplification for return to the donor. Mouse gene knockout experiments are the paradigm of what can be achieved when stem cells are targeted in culture and returned to a host. Recent developments in the characterisation and manipulation of human somatic stem cells suggest that analogous procedures might eventually be adopted for gene correction in specific tissues. Such developments will not be considered here but have been reviewed elsewhere for hemopoietic cells 8 and keratinocytes. 9 In this review, we intend to provide an overview of current advances in gene targeting and DNA recombination in higher eukaryotes, and of their possible practical applications in gene therapy. Gene targeting as an approach to gene therapy has been previously reviewed. 3, 10 Other reviews cover multiple aspects of gene targeting. 2, 6, 7, [11] [12] [13] [14] Practical aspects of gene targeting Gene targeting relies on the capacity of cells to carry out homologous recombination (HR), a process in which two DNA molecules of similar sequence interact and undergo either reciprocal exchange (as in meiotic recombination) or unidirectional transfer (as in gene conversion or recombinational DNA repair) of genetic information. HR does not require that both DNA molecules are chromosomal, and this is exploited in gene targeting where a chromosomal 'target' sequence is modified by HR with an exogenous DNA molecule, or targeting construct. Depending on the design and use of the targeting construct, a wide range of genetic modifications can be made.
14 Targeting constructs are basically vectors that carry a segment of DNA homologous to the target including, where desired, a genetic alteration to be introduced into the target locus. HR between the target and this segment can take the form of insertion or replacement events. Insertion events involve a single reciprocal exchange, resulting in the insertion of the entire construct into the target locus and duplication of the region of homology. Replacement events involve two reciprocal exchanges, or a nonreciprocal gene conversion event, and result in replacement of a stretch of the target homology with a corresponding stretch from the targeting construct. Positively selectable marker genes are usually included in targeting constructs so that drugs can be used selectively to kill untransfected cells. The ways in which such events can lead to repair of a target gene have been described elsewhere. 10 Targeting constructs are delivered to the target cells most often by electroporation, although other delivery methods can be used. Electroporation is convenient, but it is not particularly efficient; typical frequencies of cells incorporating DNA in their genomes are 10 −3 to 10
stable transfectants per electroporated cell. In mammalian cells, the great majority of stable transfectants are the result of nonhomologous recombination (NHR, or random integration) of the construct into the genome; integration by HR is generally much less efficient. Thus ratios of gene targeting to nonhomologous recombination (GT:NHR) in the range of 1:30-1:40 000 have been reported. 7, 11 Low GT:NHR ratios make gene targeting more complex since the targeted cells have to be separated from random integrants if purified populations of targeted cells are required. Several selection and screening procedures have been devised for this purpose. 10, 11 Selection procedures (eg 'promoter-trap' and 'positive/negative selection') rely on selectable marker genes carefully positioned in the targeting construct to allow selective killing of nonhomologous recombinants. Targeted cells are amenable to direct selection in the few cases when the target gene has a selectable phenotype (eg HPRT). Screening procedures are mostly based on polymerase chain reaction (PCR) assays or genomic Southern blots to detect DNA fragments unique to targeted clones. Phenotypic analysis by methods such as FACS or ELISA has also been used to screen for targeting events inducing the expression of novel membrane epitopes or the synthesis of secreted proteins, respectively. Following any initial selection or screening procedure, Southern analysis of genomic DNA from a purified clone is the most reliable and widely accepted way to confirm that the desired targeted modification has taken place. PCR assays, while extremely valuable for initial screens, are prone to contamination or other artefacts making them unsuitable as sole proof that gene targeting has occurred, especially when nonclonal populations of cells are used.
From the above it is clear that the overall targeting efficiency is determined by the efficiency of DNA delivery to the nucleus and of HR once it is there (these should be maximised) and that, for practical reasons, the efficiency of NHR should be minimised. Any protocol that can improve one or more of these three key variables without adversely affecting the others is highly desirable.
Factors that have been shown to improve gene targeting frequencies are the use of long regions of homology and isogenic DNA in the targeting construct. Targeting efficiency increases exponentially with the length of homology up to values of around 14 kbp. 15 DNA polymorphisms seem to be detrimental 15, 16 and can be avoided by using isogenic DNA, ie DNA isolated from cells of the same individual as those to be targeted. A DNA clone is only isogenic to one of the two alleles in a diploid cell, and preferential targeting of the isogenic allele has been shown to occur in chicken DT40 cells. 17 An alternative to the cumbersome procedure of making and screening isogenic genomic DNA libraries is amplification by PCR of the target region of interest. 17, 18 It is also known that linearisation of the targeting construct increases the frequency of gene targeting. [19] [20] [21] The choice of target locus and details of construct design appear to greatly influence gene targeting efficiencies but not in any clearly predictable way. 7, 11 Gene therapy as an extension of existing gene targeting experiments Gene targeting is best known for its widespread success in generating strains of mice with defined genetic alterations (usually gene knockouts). The development of procedures for the handling and amplification of mouse embryonic stem (ES) cells in culture, combined with the gene targeting technology, has permitted the almost routine production of mouse mutants for genes of interest. Established ES cell lines can thus be manipulated and amplified in culture without losing their stem cell properties and then reintroduced into the embryonic inner cell mass where they contribute to the developing embryo. 13 The isolation of ES cell lines derived from rabbits 22 and primates 23 suggests that genetic modification in other animals by gene targeting will be possible.
Targeting in ES cells permits genetic modifications to be transferred to the germ line which, for ethical and/or legal reasons, would be unacceptable in human therapy in most societies. 24 Acceptable gene therapy therefore requires modification of a patient's somatic cells and more specifically, if this is to have long-term benefits, those cells capable of both self-renewal and differentiation into the affected tissue-type (somatic stem cells). 
Gene targeting in different cell types
From the preceding discussion, it is clearly important to consider the extent to which the successes of gene targeting in mouse ES cells can be reproduced in human somatic cells. It is also of interest to assess the influence of cell-type and state of differentiation and immortalisation.
Early gene targeting experiments were carried out in transformed somatic cell lines such as mouse L cells, hamster CHO cells and human bladder carcinoma EJ cells. Targeting constructs often involved nonisogenic DNA and/or quite small regions of homology and targeting efficiencies were generally low. The great majority of gene targeting experiments, however, has been done in mouse ES cells, making use of long regions of homology and/or isogenic DNA, and efficiencies have been relatively high. There is consequently a widespread impression that ES cells are more proficient at gene targeting than primary or immortalised somatic cells. This may be so but there is no clear evidence to suggest it. Few studies have compared gene targeting frequencies in ES cells with those in other mouse cell lineages using the same targeting constructs. Two such studies suggested that F9 embryonic carcinoma cells 25 and two pre-B cell lines (BASC6-C2 and 18-8tK − ) 26 supported gene targeting as efficiently as ES cells. In a third study, 27 primary myoblasts gave an absolute targeting frequency higher than ES cells targeted with the same construct, but this reflected the greater transfection efficiency of the myoblasts, masking a lower GT:NHR ratio. The latter study was also notable for showing that primary somatic cells can support normal absolute frequencies of gene targeting with no measurable deterioration of morphology, karyotype or growth control.
The only known case of a higher eukaryote cell line with reproducibly high gene targeting efficiency is the chicken B cell line DT40. 28 In the chicken, immunoglobulin light chain variation is generated by a peculiar mechanism, in which 25 pseudo-V genes can undergo gene conversion with the only functional V locus. This process is maintained in some cell lines derived from chicken tumoral B cells, particularly the DT40 cell line. 29 The immunoglobulin light chain locus and other unrelated loci can be efficiently modified by gene targeting in this cell line with homologous recombinants accounting for 6.5-100% of stably transfected clones. 28, 30 Absolute targeting frequencies in DT40 cells do not appear to be unusually high (3.1-8.4 × 10 −6 ) 28 suggesting that NHR might be inefficient. The DT40 cell line is currently being used to study recombination. 17, 29 DT40 cells can also serve as hosts for the efficient targeted modification of human chromosomes before their transfer by microcell fusion back to mammalian cells for functional analysis. 31 Gene targeting has also been achieved in human cell lines (Table 1) and, more importantly, in several types of primary human cells (Table 2) ) similar to those described for murine cells. 7, 11 As for primary cells, retinal epithelial cells, foreskin keratinocytes and embryonic lung fibroblasts have been modified by gene targeting with absolute frequencies between 6 × 10 −8 and 4.3 × 10 −6 . 32, 33 These results show that cell immortalisation is not required to achieve normal frequencies of chromosomal gene targeting in human cells.
From the above considerations it appears that gene targeting can be performed with similar efficiencies in a variety of cell types from different species, whether transformed or primary, totipotent (ES cells) or monopotent (differentiated). Ex vivo gene targeting of nontransformed, proliferating primary somatic cells therefore seems to be a feasible strategy to introduce pre-defined modifications in the somatic genome. The next logical step towards gene therapy by gene targeting would be the ex vivo correction of mutations in nontransformed somatic cells, if possible with stem cell properties, isolated from the appropriate tissue of patients with single gene diseases.
Recent developments in gene targeting methods

Delivery methods
Nonviral vectors:
We have already mentioned that most gene targeting experiments involve electroporation, a convenient method with less tendency to result in multiple integrations than calcium phosphate transfection. Many alternative delivery methods exist (eg microinjection, optoporation, polybrene, DMSO, DEAE-dextran, many liposome formulations, viral vectors, gene gun, polyamidoamine dendrimers, synthetic peptides and combinations of some of these and other reagents) but few have been used for gene targeting and, to our knowledge, there are few systematic comparisons of transfection methods for gene targeting efficiency.
High gene targeting frequencies (1-6.7 × 10 −3
) have been obtained by microinjection of DNA constructs directly into the cell nucleus, but the GT:NHR ratios are still quite low (1:30-1:125). 21, 34 Microinjection also requires expertise and expensive equipment and the number of cells that can be conveniently microinjected is limiting. Two reports indicate that, for targeting of the APRT 35 and HPRT 36 genes in CHO cells, electroporation can give higher absolute targeting frequencies than calcium phosphate precipitation, even though the two methods gave similar nontargeted transfection efficiencies.
We have compared the efficiency of NHR and gene targeting in the human fibrosarcoma cell line HT1080 using electroporation and lipofectamine transfection. We used an isogenic, replacement-type construct that can disrupt the HPRT locus by inserting a hygromycin expression cassette in exon II. After optimising stable transfection frequencies to similar values by both methods, our preliminary results indicate that gene targeting is 10-fold more efficient by electroporation than by lipofectamine transfection (Yáñ ez and Porter, unpublished). 37 integration-deficient retroviral vectors were used to correct mutant neo genes previously integrated in chromosomes of Rat-2 and human K421b cells. Stable correction was detected at frequencies close to 3 × 10 −7 per infected cell. In all cases, however, targeting was associated with gene conversion into regions of nonhomology.
More recent studies involving adenoviral vectors have been more encouraging. Adenoviral vectors have the advantage of delivering their double-stranded DNA genome to the nucleus with high efficiencies (approaching 100%) and in a form that is naturally episomal (ie inefficient at random integration). The ability of adenovirus to infect nondividing cells is an additional attraction given potential difficulties in stimulating division of somatic stem cells. Targeting of the FGR locus with isogenic DNA in mouse ES cells using a replication-incompetent adenoviral vector produced ratios of GT:NHR as high as 1:2.5. 38 The same targeting cassette gave a ratio of 1:20 when transfected by electroporation. The absolute targeting frequencies in the adenovirus experiments were around 10 −5 , in the range described for electroporation. An earlier report described the use of replication-competent adenovirus vectors for gene targeting of the APRT locus in CHO cells. 39 In this case the GT:NHR ratio ranged from 1:5 to 1:14, a 400-fold improvement over that reported upon calcium phosphate transfection of a plasmid targeting construct. Again, the absolute targeting frequency was low, around 6 × 10
, similar to that observed in plasmid transfections. These reports therefore show encouraging ratios of GT:NHR, similar to those found routinely in chicken DT40 cells, even though no increase in the absolute targeting frequency has been achieved so far. The improved ratios of GT:NHR may or may not be offset by the additional work of constructing a targeting virus, but if absolute frequencies can be improved, adenoviral vectors could become the vectors of choice for gene therapy by gene targeting.
Manipulating target gene status
Transcription of target gene: Targeted modification of the ␤-globin gene in human EJ cells 40 and of the adipsin and adipocyte P2 genes in mouse ES cells 41 established that transcription of the target gene is not required for gene targeting. It has been reported, however, that transcription stimulates both extrachromosomal HR in CHO cells 42 and gene targeting in HT1080 cells. 43 Both strategies involved recombination between two defective neo genes and made use of the dexamethasone-inducible MMTV promoter to drive transcription of both substrates (extrachromosomal HR) or of the target gene (gene targeting). HR was scored as the frequency of neo + colonies, and stimulation upon transcription ranged from 3-to Ͼ20-fold. In contrast, no report is available on the effect of transcription on gene targeting of endogenous mammalian genes. To address this question we have targeted the IFN-inducible 6-16 gene in HT1080 cells. The promoter-trap targeting construct was used as previously described 44 except that it was reconstructed using isogenic (HT1080) DNA. Transcription from the 6-16 promoter was induced by IFN treatment and controls were performed to account for any nonspecific effects of IFN. We could detect no variation in targeting frequency that correlated with the transcriptional status of the 6-16 gene (Yáñ ez and Porter, unpublished). Thus, the increase in targeting frequencies observed with exogenous target genes may not be a general phenomenon.
Cleavage of target locus: It has been recently shown that introduction of a double-stranded break (DSB) in the genomic DNA of the target locus can increase targeting frequencies. The strategies used to show this were similar in several cell lines. Defective marker genes were engineered in vitro by insertion of the recognition site for the S. cerevisiae DNA endonuclease I-SceI. Stable transfectants of the marker are sensitive to the selective drug, but can become resistant after HR with a construct containing wild-type marker sequences. Cleavage at the I-SceI site, induced by expressing the I-SceI gene in vivo or electroporating purified enzyme, stimulate gene targeting 50-fold to 10 4 -fold variously in mouse ES, 3T3 and PCC-7 cells, and hamster CHO cells. [45] [46] [47] [48] The extent of the effect may depend on cell type since in CHO cells gene targeting was stimulated by three to four orders of magnitude 48 while no stimulation was observed in mouse Ltk − cells. 49 It is worth noting that target gene-specific DSBs may be mutagenic, as well as having a stimulatory effect on HR. Thus, in an assay for I-SceI-induced loss of APRT gene function in CHO cells, I-SceI stimulated HR about 100-fold but NHR was stimulated more than 1000-fold, and point mutations about 10-fold. 50 For a practical application of target-specific cleavage in single-step targeting strategies, an alternative to engineered I-SceI recognition sites must be found. If oligonucleotides able to form triple DNA helices upon binding to their polypurine target site 51 could be linked to DSB-inducing agents, cleavage of specific sequences in the target locus might be feasible.
Design of targeting constructs
Optimising promoter-trap constructs: Promoter-trapbased targeting involves DNA constructs containing promoterless selectable marker genes that become activated by the target gene promoter following HR. These strategies can make use of the varying efficiency of different selectable markers to generate resistance to their corresponding selective drug. Several positively selectable markers have shown up to 200-fold differences in their ability to generate resistant colonies in rat-1 cells when transfected as promoterless constructs. 52 Using a combined promoter-trap and positive-negative selection system, it has been shown that some markers may be too weak to render targeted, drug-resistant clones when the level of expression of the target gene is low. Matching the expression level of the target gene (c-MYC), the strength of the selectable marker in the targeting construct and the selection stringency (drug concentration) has led to Ͼ60-fold improvements in GT:NHR ratio. This was due to selective loss of nonhomologous recombinants, with absolute targeting frequencies remaining unchanged.
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DNA end-modifications: Modification of DNA ends in the transfected molecules might also be a way to reduce NHR and even to improve HR. Dideoxynucleotides added to the 3Ј ends of a linear plasmid transfected into monkey COS-1 cells increased the intramolecular HR:end-joining (NHR) ratio about five-fold. 53 To our knowledge, use of this treatment in targeting experiments has not been reported so far. A preliminary report does state, however, that ligation of linear targeting constructs to self-complementary oligonucleotides, to seal the DNA ends, enhances stability of the DNA in transfected cells and increases the frequency of gene targeting. 54 Use of oligonucleotides and small DNA fragments: Two recent reports describe dramatically improved gene targeting frequencies using either chimeric DNA-RNA oligonucleotides 55 or small denatured DNA fragments. 56 The possibility of using small nucleic acids for gene targeting is attractive. Sufficiently small molecules can be synthesised on a large scale, if necessary with chemical modifications to improve stability, and without the worry of biological contamination. Unfortunately, the logarithmic relationship between targeting efficiency and length of homology suggests that simple nucleic acids with small regions of homology will not be efficient.
The stimulus for the experiments of the Kmiec laboratory was their observation that RNA-DNA hybrids were more active in homologous pairing reactions than corresponding DNA duplexes. 57 Chimeric, self-complementary DNA-RNA oligonucleotides were therefore designed for correction of the single nucleotide mutation in the chromosomal ␤-globin gene of immortalised B cells from a patient with sickle-cell anaemia. 55 In these oligonucleotides, selffolding creates hairpin ends flanking 25 bp of homology to the target locus. The noncoding strand in the oligonucleotide contains two 10-nt long 2Ј-O-methyl RNA stretches flanking a 5 bp DNA sequence, with the wildtype version of the mutated nucleotide in the central position. The hairpin ends and modified ribonucleotides may protect the oligonucleotides from degradation. Oligonucleotides were transfected using DOTAP liposomes. Transfections were allowed to proceed for 6 h, after which the entire, mixed population of cells was harvested and assayed for corrected globin alleles by Southern analysis and PCR. The intensities of the corrected and uncorrected bands in the Southern analysis were similar, suggesting that approximately 50% of the target alleles had been corrected. 55 This remarkable result clearly has huge implications for the feasibility of gene therapy by gene targeting. However, as has already been pointed out, 58, 59 further controls are required to rule out the possibilities of screening artefacts and cell contamination. An unambiguous demonstration of targeted correction would involve the isolation of a clonal cell population bearing both a corrected ␤-globin allele (as judged by Southern analysis), and an otherwise patient-specific genotype (as judged eg by DNA-fingerprint analyses).
Small DNA fragments have been used to target the 3-bp deletion (⌬F 508) of the cystic fibrosis transmembrane regulator (CFTR) gene in transformed lung epithelial cells from a patient with cystic fibrosis. 56 The targeting construct was a denatured 491 bp PCR product derived from a functional CFTR gene. This DNA fragment was combined with purified E. coli recA protein (see below) in some experiments before transfection by electroporation, polyamidoamine dendrimers or gramicidin S-liposome complexes. Screening for CFTR correction was by allelespecific, PCR-based Southern blots and functional Cl − conductance analyses, but genomic Southern blots of clonal cell populations were not carried out. The reason for the apparently high targeting efficiency, estimated as close to 10 −2 , remains unclear. The different transfection procedures gave similar targeting frequencies, suggesting that the high frequencies were not due to the choice of transfection method or the use of recA protein. The use of single-stranded vectors for gene targeting has been reported before, and did not seem to produce an improvement. 43, 60 It has also been reported that targeting with approximately 700-bp-long targeting constructs in mouse ES cells 47 and hamster CHO cells 48 is undetectable (Ͻ6.3 × 10 −7 ) unless the genomic DNA is linearised at the target locus. Thus, as one would predict from earlier studies, 15 high targeting frequencies are not generally obtained when small targeting constructs are used.
Treatment of host cells
Growth and selection conditions: Careful optimisation of cell growth conditions both before and after transfection may have a drastic effect on measurable targeting efficiency. Thus targeting frequencies in mouse ES cells were found to keep an inverse linear correlation with cell doubling times, and differences of up to 14-fold were obtained by varying the amount of foetal calf serum. 61 Also, HR between co-injected plasmids peaks in earlyto mid-S phase in rat-20 cells 62 suggesting that cell cycle synchronisation might be a way to improve gene targeting efficiencies.
In a recent report of gene targeting at the HPRT locus in ES cells, absolute targeting efficiencies were improved from 0.001 to 20% by the use of an optimised gene targeting protocol. A key feature of this protocol appears to have been the plating of cells after electroporation at unusually high densities and delaying selection for at least 60 h. 63 This dramatic improvement would be significant for gene therapy if it can be reproduced at other loci and in other cell lines.
Poly(ADP ribose) polymerase (PARP) inhibition: PARP is an abundant nuclear enzyme activated by binding to a particular type of DNA lesion, single-strand breaks. PARP itself appears to be the main target for ADP-ribosylation, and this modification seems to precede DNA repair. 64, 65 It has been reported that inhibition of PARP reduces both random genomic integration of exogenous constructs 66, 67 and the integration of the retroviral genome in the host cell DNA. 68 This reduction in NHR led to the reasoning that 3-methoxybenzamide (3-MB)-inhibition of PARP might be a way to enrich for targeted clones in gene targeting experiments. 36 The hypothesis was tested by targeting a hemizygous 3-bp deletion mutant of the mouse APRT gene in CHO cells. Treatment of the cells with 3-MB led to a reduction in the frequency of both gene targeting and NHR, the effect being more pronounced for the latter. Thus, the authors report an enrichment for targeted clones of up to 100-fold, even though the absolute targeting frequency was reduced two-to 13-fold. Curiously, the enrichment was dependent on the DNA delivery method, being observed with calcium phosphate transfection but not with electroporation. An undesirable consequence of using calcium phosphate was the high frequency of concomitant random integration events (50-64%) observed in targeted colonies.
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MSH2 gene inactivation: Non-isogenic sequences impair intra-and inter-chromosomal HR, 69, 70 and this has been interpreted as a defensive mechanism against potentially deleterious ectopic DNA recombination between diverged sequences. Isogenic DNA is also more efficient in gene targeting 15, 16 and this has recently been linked to the action of DNA mismatch repair mechanisms. The mammalian gene MSH2 is a homologue of bacterial MutS, whose protein product binds to base mispairs and loops of up to four unpaired nucleotides, triggering the mutSL pathway of DNA mismatch repair in E. coli. The human hMSH2 gene is defective in hereditary nonpolyposis colorectal cancer. 71 The mouse homologue of MSH2 has been disrupted in ES cells, and extracts from homozygous MSH2−/− cells are defective in DNA mismatch-binding proteins in vitro. Gene targeting of the retinoblastoma locus was found to occur as efficiently with a non-isogenic targeting construct as with an isogenic one in the MSH2−/− ES cells. 72 If inhibitors of mismatch repair become available, they could be used to block the process temporarily in cells undergoing HR with non-isogenic constructs. Alternatively, proteins such as E. coli recA, 73 RuvAB 74 or the gene 4 helicase of bacteriophage T7, 75 which allow HR to proceed through mismatches and nonhomologous patches, might usefully be incorporated into a targeting strategy. This could be particularly important in gene therapy procedures relying on gene targeting, when the use of a standard, non-isogenic construct would be most convenient.
DNA damage: Several types of DNA damage have been shown to increase HR in eukaryotic cells. These include lesions caused by chemical carcinogens, 76 UV irradiation, 77 gamma irradiation 78 and photoreactive molecules. 79 Another type of DNA damage is the presence of uracil residues substituting for thymine, and this seems to be recombinogenic in some phage and bacterial systems. 80, 81 We have used uracil-containing targeting constructs, prepared from dut ung E. coli strains, in our previously mentioned HPRT and 6-16 targeting systems in HT1080 cells. The presence of uracil was detrimental to both gene targeting and NHR, the effect being more marked for the former (Yáñ ez and Porter, unpublished).
The mutagenic agents mentioned above essentially cause random DNA damage, which is not a desirable outcome in gene targeting procedures. Target DNAspecific techniques are potentially more attractive. In this respect, it has recently been shown that triplex-forming oligonucleotides bound to photoreactive molecules can cause sequence-specific DNA damage around the target site for the oligonucleotide, and this can induce HR. 82 This could be a way to direct HR activities to the desired DNA region in gene targeting experiments.
Recent advances in DNA recombination
The past few years have brought considerable advances in our understanding of the mechanisms of recombination in eukaryotes and their roles in DSB repair. In yeast, where transfected DNA integrates mostly by HR, the predominant pathway for DSB repair involves HR. Although an analogous pathway exists in higher eukaryotes, it appears to have a more specialised role, and DSB repair occurs preferentially by end-joining (NHR). The key players in these two pathways have now been identified: the RAD52 group of proteins for HR and a DNAdependent protein kinase and associated proteins for NHR. If we could understand the way cells control the balance between these two pathways, we might be able to devise methods to reverse the bias towards NHR in gene targeting procedures.
HR proteins in higher eukaryotes
Genetic studies in bacteria and yeast have uncovered some key players in HR pathways, and the search for homologous genes in higher eukaryotes has proved to be extremely rewarding. In E. coli, recA mutants profoundly affect HR, inhibiting the process up to 10 4 -fold. recA protein is a single-stranded DNA-dependent ATPase that catalyses homologous pairing and strand exchange between the DNA substrates in HR. 73 In S. cerevisiae, HR is mediated by the genes of the RAD52 epistasis group, of which RAD51 (the yeast homologue of recA), RAD52 and RAD54 are particularly important. 83 Humans and other higher eukaryotes encode homologues of these three genes. [84] [85] [86] The RAD51 84 and RAD54 86 genes of higher eukaryotes are expressed at particularly high levels in spleen, thymus and testis, and at low levels in all other tissues tested. This might also be the case for RAD52. 85, 87 Recent results suggest that these genes play a role in proliferating cells, which are present at high levels in immune tissues and gonads. However, the gonads support meiotic DNA recombination, and the thymus is the tissue where V(D)J recombination (a site-specific type of NHR) of T cell receptor genes takes place. The possible involvement of RAD51, RAD52 and RAD54 in these processes is also under investigation.
The human RAD51 protein is a DNA-dependent ATPase able to promote homologous pairing and strand exchange in vitro, albeit less efficiently than its E. coli counterpart, recA. 88 The disruption of the mouse homologue of RAD51 produces an early embryonic lethal phenotype. Additionally, no RAD51−/− ES or F9 cells could be produced, and no cells could be grown from the early embryos. 89, 90 A conditional RAD51−/− cell line has been obtained from chicken DT40 cells upon expression of the human RAD51 gene as a repressible transgene and sequential targeting of the endogenous RAD51 loci. If the human transgene is repressed, RAD51−/− cells accumulate chromosomal aberrations and arrest in the G 2 /M phases of the cell cycle, and this is followed by DNA degradation and massive cell death. The authors conclude that DSBs generated during DNA replication are repaired by RAD51-mediated recombinational repair, this being an essential role in higher eukaryotes. 91 The key importance of RAD51 is underscored by its interaction with three tumour suppressors: p53, 92 and breast cancer BRCA1 93 and BRCA2. 94, 95 The biochemical information available for RAD52 indicates that the protein can promote annealing of homologous single-stranded DNA molecules, and strand transfer between homologous single-stranded and doublestranded DNA substrates. [96] [97] [98] 99 and of the human gene in monkey FSH2 cells 100 stimulates extrachromosomal and intrachromosomal HR, respectively, and confers increased resistance to ionising radiation. These results suggest that the cellular machinery for HR can be stimulated by over-expression of some of the relevant genes.
The RAD54 protein is a putative helicase of the SNF2/SWI2 family. 86 The mouse RAD54 gene knockout has shown that this gene is dispensable for V(D)J recombination and meiosis, RAD54−/− mice having normal B and T cell populations and producing offspring. However, RAD54−/− mouse ES cells are hypersensitive to DSB-causing agents, and exhibit reduced gene targeting frequencies compared with wild-type cells.
101 RAD54−/− mutants of the chicken B cell line DT40 are also hypersensitive to ionising radiation, and have seven-fold reduced gene conversion frequencies. In contrast, gene targeting frequencies are reduced by at least two orders of magnitude in RAD54−/− chicken cells, suggesting a high dependence on RAD54. 17 These reports 17, 101 have provided genetic evidence of the relationship between DSB repair, HR and gene targeting in higher eukaryotes.
The first attempts to find practical applications for homologous recombination proteins in gene targeting procedures are already ongoing. Targeting constructs have been pre-incubated with purified E. coli recA protein before transfection by electroporation, polyamidoamine dendrimers and gramicidin S-liposome complexes, and this treatment did not seem to increase targeting frequencies. 56 Experiments in which the targeting construct is pre-incubated with purified human RAD51 protein before transfection are reported to be underway. 102 
NHR in higher eukaryotes
The analysis of several sets of mammalian cell lines hypersensitive to ionising radiation has revealed four complementation groups of defects in DSB repair. Three of these have been mapped to the genes encoding the three subunits of DNA-dependent protein kinase (DNA-PK): Ku70, Ku80 and the catalytic subunit DNA-PKcs. 103 The fourth group corresponds to the XRCC-4 gene. 104 V(D)J recombination is impaired in Ku, DNA-PKcs or XRCC4-deficient cell lines, providing a genetic link between that process and DSB repair. The Ku70-Ku80 dimer is a DNA-binding protein specific for DNA ends. Upon DNA end-binding, Ku recruits DNA-PKcs to the site of DNA damage, and this enzyme becomes activated. 103 On the other hand, XRCC-4 binds to and stimulates DNA ligase IV, which might be involved in the final steps of DNA end-joining. 105, 106 Using I-SceI-induced chromosomal DSBs, it has been shown that Ku80-deficient CHO cells are impaired in end-joining, while they are proficient in gene targeting and DNA repair by HR. 48 Additionally, Ku80-deficient CHO cells have reduced stable transfection frequencies under some conditions. 48, 107 These data show that NHR can be specifically impaired in mammalian cells without affecting HR.
It has been recently shown that DNA-PKcs 108 and the ataxia telangectasia gene product ATM 109 interact constitutively with the protein tyrosine kinase c-Abl. Functional ATM is required for ionising radiation-induced activation of c-Abl, and DNA damage promotes a physical association of c-Abl and p53. 110 Thus, p53 seems to interact with both NHR and HR pathways, and it has been hypothesised that it might control the way DNA repair of DSBs is performed. 92 
Final remarks
The past few years have provided substantial advances in our understanding of several aspects of gene targeting in cells of higher eukaryotes. Human cells can be modified by gene targeting at frequencies similar to those described for other vertebrates. The ratio of GT:NHR can be improved by using adenoviral vectors for DNA delivery, and the absolute targeting frequency can be greatly increased by induced DSBs in the target locus. The expected relationship between gene targeting and DNA repair by HR has been confirmed, and we now know a handful of proteins involved in the process. This wealth of new data may lead to more efficient ways of DNA delivery for gene targeting, possible targets for inhibitors of undesirable NHR, and proteins that could be manipulated in targeting strategies.
Many old and new questions remain unanswered. We do not understand why different loci appear to target at different frequencies, and whether this may be related to epigenetic factors such as DNA methylation or chromatin condensation. It is unknown how the proteins of HR are recruited to the DSB, and little is known about the decision making that drives DSB repair to NHR or HR.
In vivo gene therapy by gene targeting is not viable at present. However, several types of human tissue-specific stem cells can be isolated and subjected to ex vivo amplification and manipulation. This opens the possibility of selecting and expanding cells that have undergone gene targeting. Nontransformed, proliferating human cells have already been modified ex vivo by gene targeting. The next step towards gene therapy by gene targeting in human cells could be the actual correction of the DNA defect in nontransformed cells from patients with singlegene disorders.
